Analyst Consensus ?
ConsensusHold23 ratings
Bullish1356.5%
Neutral939.1%
Bearish14.4%
IDEXX Laboratories, Inc. · IDXX · FY2026 Q2 · Calendar Q3 2026
IDEXX raises 2026 guidance as diagnostics growth remains broad-based
The supplied evidence supports a constructive operating trajectory for IDEXX: recurring diagnostics demand, product adoption, international growth, and new workflow offerings are supporting momentum. The thesis remains dependent on execution in inVue Dx and Cancer Dx, stable U.S. clinic activity, and the ability to fund expansion without materially weakening margins.
Reported Before market openNASDAQHealthcare
$41.14B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$4.27
Consensus $3.94
EPS surprise
+8.4%
Reported versus consensus
Reported revenue
$1.22B
Consensus $1.20B
Revenue surprise
+1.4%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+3.6%
Event window
SPY move
+1.8%
Same window
Abnormal move
+1.8%
Stock minus SPY
Volume
2.6×
Versus trailing sessions
Subsequent drift
-7.3%
Up to 20 sessions
IDXXSPY benchmark
Ask FN2 about IDXX FY2026 Q2
Transcript, numbers and history already loaded
Why did IDXX rise 3.6% after beating EPS estimates in FY2026 Q2?What changed in IDXX's guidance and outlook in FY2026 Q2?Give me the bull and bear case for IDXX after FY2026 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior quarter, the supplied analysis shows continued broad-based growth, further inVue Dx adoption, expanded Cancer Dx and Catalyst initiatives, and raised full-year guidance. New information included stronger Water and LPD organic growth, more than 10,000 Cancer Dx clinic orders, and SDMA availability on the Catalyst CLIP menu.
Guidance delta
Full-year 2026 revenue and EPS guidance was raised, with the operating-margin target also improved.
Key takeaways
- Management highlighted roughly 10% year-over-year revenue growth, recurring CAG Diagnostics strength, and double-digit growth in Water and LPD.
- inVue Dx placements reached 5,265 units in Q2 and remained on track for the full-year goal.
- Cancer Dx, SDMA integration, software and AI capabilities, and international expansion were identified as ongoing growth levers.
- The main offsets were softer U.S. wellness visits, foreign-exchange headwinds, and investment-related margin pressure.
Management priorities
- Complete the inVue Dx FNA rollout and expand the platform's consumables opportunity.
- Extend the Cancer Dx menu and broaden Catalyst assays, including SDMA CLIPs.
- Expand international field coverage and continue software and AI investment across Vello and VetConnect PLUS.
- Maintain product-led utilization growth through diagnostics, imaging, and workflow offerings.
Follow IDXX with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$521.5Current
$247Low
$637.65Average
$830High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Sep 23, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Barclays | Overweight | Overweight | Maintain | Aug 11, 2026 |
| UBS | Neutral | Neutral | Maintain | Aug 5, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Aug 5, 2026 |
| Stifel | Buy | Buy | Maintain | Mar 31, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | Feb 9, 2026 |
| BTIG | Buy | Buy | Maintain | Feb 3, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Nov 4, 2025 |
| JP Morgan | Overweight | Overweight | Maintain | Nov 4, 2025 |
| Leerink Partners | Outperform | Outperform | Maintain | Jul 17, 2025 |
| B of A Securities | Neutral | Neutral | Maintain | Apr 21, 2025 |
| Goldman Sachs | Buy | Buy | Maintain | Jan 17, 2024 |
| Atlantic Equities | Neutral | Overweight | Downgrade | Aug 2, 2023 |
| Credit Suisse | Outperform | Outperform | Maintain | Aug 13, 2021 |
| Guggenheim | Neutral | Buy | Downgrade | Jul 12, 2021 |
| Stifel Nicolaus | Buy | Buy | Maintain | Jul 22, 2019 |
| Canaccord Genuity | Buy | Buy | Maintain | May 2, 2019 |
| Bank of America | Buy | Buy | Maintain | Nov 2, 2018 |
| PiperJaffray | Overweight | Overweight | Maintain | Jan 16, 2018 |
| Aegis Capital | Sell | Sell | Maintain | Jun 1, 2017 |
| CL King | Neutral | Neutral | Maintain | Apr 1, 2016 |
| Raymond James | Market Perform | Outperform | Downgrade | Aug 28, 2015 |
| Feltl & Co. | Hold | Sell | Upgrade | Jul 23, 2015 |
| Bank oferica | Buy | Buy | Maintain | Apr 20, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $521.5. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Barclays | Glen Santangelo | $710 | $595.76 | +36.1% | Aug 11, 2026 |
| UBS | Analyst unavailable | $620 | $559.86 | +18.9% | Jul 27, 2026 |
| UBS | Andrea Alfonso | $640 | $569.17 | +22.7% | Apr 28, 2026 |
| Piper Sandler | Analyst unavailable | $750 | $644.61 | +43.8% | Feb 9, 2026 |
| Barclays | Glen Santangelo | $800 | $642.94 | +53.4% | Feb 5, 2026 |
| UBS | Andrea Alfonso | $730 | $639.6 | +40.0% | Feb 3, 2026 |
| BTIG | Analyst unavailable | $800 | $639.6 | +53.4% | Feb 3, 2026 |
| Barclays | Glen Santangelo | $850 | $706.65 | +63.0% | Dec 8, 2025 |
| Morgan Stanley | Analyst unavailable | $805 | $721.04 | +54.4% | Nov 4, 2025 |
| UBS | Analyst unavailable | $750 | $722.94 | +43.8% | Nov 4, 2025 |
| BTIG | Analyst unavailable | $830 | $722.94 | +59.2% | Nov 4, 2025 |
| Jefferies | Keith Devas | $830 | $722.94 | +59.2% | Nov 4, 2025 |
| Leerink Partners | Analyst unavailable | $785 | $722.94 | +50.5% | Nov 3, 2025 |
| Stifel Nicolaus | Jonathan Block | $775 | $722.94 | +48.6% | Nov 3, 2025 |
| Stifel Nicolaus | Jonathan Block | $700 | $628.54 | +34.2% | Oct 31, 2025 |
| UBS | Andrea Alfonso | $720 | $638.89 | +38.1% | Oct 1, 2025 |
| Morgan Stanley | Analyst unavailable | $722 | $641.94 | +38.4% | Aug 5, 2025 |
| BTIG | Analyst unavailable | $785 | $641.94 | +50.5% | Aug 5, 2025 |
| Stifel Nicolaus | Analyst unavailable | $640 | $682.78 | +22.7% | Aug 4, 2025 |
| Stifel Nicolaus | Jonathan Block | $510 | $495.73 | -2.2% | Jun 24, 2024 |
| Barclays | Analyst unavailable | $590 | $507.68 | +13.1% | Feb 8, 2023 |
| J.P. Morgan | Analyst unavailable | $550 | $487.04 | +5.5% | Feb 7, 2023 |
| Atlantic Equities | Analyst unavailable | $600 | $485.53 | +15.1% | Feb 7, 2023 |
| Oppenheimer | Analyst unavailable | $247 | $483.2 | -52.6% | Feb 2, 2023 |
| Citigroup | Analyst unavailable | $268 | $483.2 | -48.6% | Feb 2, 2023 |
| Citigroup | Analyst unavailable | $273 | $420.63 | -47.7% | Dec 9, 2022 |
| Morgan Stanley | Analyst unavailable | $543 | $435.78 | +4.1% | Nov 15, 2022 |
| Stifel Nicolaus | Analyst unavailable | $500 | $355.62 | -4.1% | Jun 24, 2022 |
| Goldman Sachs | Analyst unavailable | $530 | $357.33 | +1.6% | May 19, 2022 |
| Barclays | Balaji Prasad | $700 | $364.5 | +34.2% | May 6, 2022 |
Track every rating change on IDXX the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationIDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services.…
Historical context
All IDXX earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| COO The Cooper Companies, Inc. | FY2026 Q3 · Calendar Q3 2026 | +2.7% | -14.7% | CooperCompanies beats expectations as inventory reduction weighs on vision revenue |
| MDT Medtronic plc | FY2027 Q1 · Calendar Q3 2026 | +4.3% | +1.5% | Medtronic raises FY27 outlook as growth broadens across platforms |
| A Agilent Technologies, Inc. | FY2026 Q3 · Calendar Q3 2026 | +8.7% | +1.7% | Agilent raises outlook after Q3 beat; Ignite drives margin gains |
Latest beats and misses
Who reports nextBeat on EPS
- FPSFY2026 Q4 · September 15, 2026+4.3% EPS+9.5% move
- TCOMFY2026 Q2 · September 15, 2026+22.3% EPS+3.0% move
- KRFY2026 Q2 · September 11, 2026+2.8% EPS+2.7% move
- ADBEFY2026 Q3 · September 10, 2026+0.8% EPS+1.4% move
- ORCLFY2027 Q1 · September 10, 2026+10.3% EPS-1.7% move
- CASYFY2027 Q1 · September 8, 2026+8.7% EPS-14.2% move
Get the IDXX recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-08-04T18:08:48.346437+00:00
- FN2 earnings calendar · 2026-09-09T01:23:14.388487+00:00
- Polygon adjusted daily market bars · 2026-09-23T03:00:55.417039+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-09-23T03:00:55.414809+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-09-23. For educational purposes only; not investment advice.